MED-LIFE DISCOVERIES
Plasmalogens RCDP Neurological
PlasmalogensRCDPNeurological
MED-LIFE DISCOVERIES
Q&A: Approved drugs versus supplements
Q&A: Approved drugs versus supplements
Tara SmithApril 10, 2025
MLD announces publication of RhizoQOL survey
MLD announces publication of RhizoQOL survey
Tara SmithMarch 31, 2025
First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD
First human safety and pharmacokinetic study of a plasmalogen augmentation therapy published by MLD
Tara SmithMarch 17, 2025
MLD announces plans for Rare Disease Day 2025
MLD announces plans for Rare Disease Day 2025
Tara SmithJanuary 16, 2025
MLD attending CORD Conference 2024
MLD attending CORD Conference 2024
Kaeli KnudsenNovember 18, 2024
MLD to present at World Orphan Drug Congress Europe
MLD to present at World Orphan Drug Congress Europe
Tara SmithOctober 9, 2024
MLD publishes world's first chronic plasmalogen-deficient Alzheimer's mouse model
MLD publishes world's first chronic plasmalogen-deficient Alzheimer's mouse model
Tara SmithJuly 24, 2024
Patient-Focused Drug Development Session
Patient-Focused Drug Development Session
Tara SmithMay 8, 2024
MLD attending World Orphan Drug Congress 2024
MLD attending World Orphan Drug Congress 2024
Kaeli KnudsenApril 2, 2024
Rare Disease Day 2024 Coloring Contest Rules
Rare Disease Day 2024 Coloring Contest Rules
Shawn RitchieFebruary 15, 2024
MLD Presenting at AD/PD Conference
MLD Presenting at AD/PD Conference
Tara SmithFebruary 9, 2024
MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial
MLD Announces Completion of Dosing with Plasmalogen-precursor PPI-1011 in its Phase I Clinical Trial
Shawn RitchieFebruary 6, 2024
Multiple ascending dose study of PPI-1011 begins dosing
Multiple ascending dose study of PPI-1011 begins dosing
Tara SmithDecember 10, 2023
MLD to attend Canadian Conference on Dementia
MLD to attend Canadian Conference on Dementia
Tara SmithSeptember 28, 2023
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011
SASKATOON-BASED BIOPHARMA COMPANY MED-LIFE DISCOVERIES RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA TO BEGIN A HEALTHY ADULT PHASE 1 TRIAL FOR PPI-1011
Tara SmithJune 6, 2023
MLD attending Rhizokids International Conference in Alabama
MLD attending Rhizokids International Conference in Alabama
Kaeli KnudsenApril 12, 2023
MLD attending International Plasmalogen Conference
MLD attending International Plasmalogen Conference
Tara SmithApril 6, 2023
MLD attending BioPharm America
MLD attending BioPharm America
Tara SmithSeptember 6, 2022
MLD attending World Orphan Drug Congress 2022
MLD attending World Orphan Drug Congress 2022
Tara SmithJune 28, 2022
MLD presenting at AAIC 2022
MLD presenting at AAIC 2022
Tara SmithJune 14, 2022
Older

© 2024 MED-LIFE DISCOVERIES LP

Suite 407, 15 Innovation BLVD
Saskatoon, SK Canada. S7N 2X8 306-244-8233

Corporate
News Legal